Curr Health Sci J, vol. 47, no. 2, 2021

Different Age Related Neurological and Cardiac Effects of Verapamil on a Transgenic Mouse Model of Alzheimer's Disease

[Original Paper]

Alexandru Cojocaru(1,2), Alexandra Daniela Zavaleanu(1,3), Daniela Cornelia Calina(4), Dan Ionut Gheonea(3), Eugen Osiac(1,5), Ianis Kevyn Stefan Boboc(2,3), Smaranda Ioana Mitran(1)


(1)Department of Physiology, University of Medicine and Pharmacy of Craiova, Craiova, Romania,
(2)Experimental Research Center for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Romania,
(4)Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Romania,
(5)Department of Biophysics, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Dementias are the third cause of the disability-adjusted life-years (DALYs) worldwide with Alzheimer’s (AD) having the highest prevalence. Despite ample research in the field, therapeutic options are limited. However, with the increase in lifespan, a larger number of AD patients will receive other medication for the evermore-increased number of comorbidities that such patients face. The purpose of this study was to evaluate the neurological and cardiac effects of verapamil, on C57BL/6J-TgN (Thy1-APPKM670/671NL; Thy1-PS1L166P (APP) mice. The daily administration of 3.5mg/kg of verapamil for 28 days revealed different effects on young and aged APP mice. While young animals showed less anxiety and improved short-term memory with minimal cardiac effects (an increase in the duration of ventricular depolarization), aged ones did not present behavioral improvements, but with a decrease in the duration of ventricular depolarizing. Repolarization effects of verapamil were similar in young and aged animals, except for the duration of the ST segment that was longer in aged animals. Considering our results, the use of calcium blockers in AD patients should take into consideration the stage of the disease, as different effects could be seen at different stages of AD, in our model.


Keywords:
Calcium blockers, Alzheimer’s, age



Corresponding:
Ianis Kevyn Stefan Boboc, Experimental Research Center for Normal and Pathological Aging, Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, e-mail: kevynboboc@gmail.com


DOI 10.12865/CHSJ.47.02.17 - Download PDF